Condition: Lymphoid Malignancies · Sponsor: AVM Biotechnology Inc
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.
This description comes directly from the study's public registry record.
Theresa Deisher, PhD · 206-851-3942 · tdeisher@avmbiotech.com
Sandeep Mittal, PhD · 346-401-4303 · smittal@avmbiotech.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| Los Angeles Cancer Network | Los Angeles, California, United States | Recruiting |
| UCLA Medical Center of Hematology/Oncology | Los Angeles, California, United States | Recruiting |
| Innovative Clinical Research Institute | Whittier, California, United States | Recruiting |
| ASCLEPES Research Centers | Weeki Wachee, Florida, United States | Recruiting |
| University of Illinois at Chicago Cancer Center | Chicago, Illinois, United States | Recruiting |
| Norton Cancer Institute | Louisville, Kentucky, United States | Recruiting |
| Oncology Hematology West P.C. dba Nebraska Cancer Specialists | Omaha, Nebraska, United States | Recruiting |
| Gabrail Cancer Center Research, | Canton, Ohio, United States | Recruiting |
| Baptist Clinical Research Institute | Memphis, Tennessee, United States | Recruiting |
| University of Texas(UT) Southwestern-Children's Medical Center | Dallas, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04329728